Nanosonics FY26 revenue rises 3% to 203.9M

• Nanosonics reported a 3% increase in annual revenue to $203.9 million for fiscal year 2026.
• The company announced a new share buyback programme of up to $40 million.
• Commercial growth was driven by record North American upgrades and expanding adoption of next-generation trophon devices.

Infection prevention company Nanosonics (ASX:NAN) increased its annual revenue by 3% to $203.9 million for the financial year ended June 30.

The top-line result was impacted by a strengthening Australian dollar, with revenue growing 6% on a constant currency basis to $211.5 million.

"The trophon-only business continued to demonstrate strong profitability, cash generation and improved operating leverage, with EBIT growth of 5% to $50.6 million or constant currency EBIT growth of 16% to $56.5 million," said Nanosonics CEO and President Michael Kavanagh.

Earnings before interest and tax dropped 10% to $16 million in reported terms, though constant currency EBIT rose 21% to $21.6 million.

The company closed the period with cash and cash equivalents of $155.2 million following the execution of $20 million.

Following the announcement, the Nanosonics share price was down at $3.05.

Total global trophon unit placements expanded by 9% during the period to reach 4,230 units, taking the global cumulative installed base to 39,230 devices.

Nanosonics plans to launch its new CORIS platform across the UK, Ireland, and Australia in the first half of fiscal year 2027, with a rollout in the US scheduled to follow.